USPTO serial 79438025
K
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- HUDSON, TAMARA BREE
- Law office
- TMEG LAW OFFICE 104
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with K?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew D. Bochner
Andrew D. Bochner Bochner PLLC1040 Avenue of the Americas15th FloorNew York, NY 10018Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable or recorded databases in the fields of medical and biomedical research and development, medical diagnosis and treatment, clinical trials, and drug discovery and development; downloadable or recorded software for diagnosing medical conditions, prescribing medical treatment and prescriptions, researching the clinical trial landscape and data, designing clinical trials and forecasting clinical trial results, searching for clinical trial patients, analyzing medical images, analyzing data, developing pharmaceutical products and chemical compounds; downloadable or recorded software for prioritizing targets, assessing tractability and drugability, characterizing patient subgroups, generating reports, validating biomarkers across modalities, and connecting biology to clinical outcomes; downloadable or recorded application software for diagnosing medical conditions, prescribing medical treatment and prescriptions, researching the clinical trial landscape and data, designing clinical trials and forecasting clinical trial results, searching for clinical trial patients, analyzing medical images, analyzing data, developing pharmaceutical products and chemical compounds; downloadable or recorded application software for prioritizing targets, assessing tractability and drugability, characterizing patient subgroups, generating reports, validating biomarkers across modalities, and connecting biology to clinical outcomes; scientific laboratory research devices for DNA analysis, namely, for analyzing genome information; downloadable or recorded artificial intelligence software for healthcare, namely, diagnosing medical conditions, prescribing medical treatment and prescriptions, researching the clinical trial landscape and data, designing clinical trials and forecasting clinical trial results, searching for clinical trial patients, analyzing medical images, analyzing data, developing pharmaceutical products and chemical compounds; downloadable or recorded artificial intelligence software for healthcare, namely, for prioritizing targets, assessing tractability and drugability, characterizing patient subgroups, generating reports, validating biomarkers across modalities, and connecting biology to clinical outcomes; downloadable or recorded computer application software for diagnosing medical conditions, prescribing medical treatment and prescriptions, researching the clinical trial landscape and data, designing clinical trials and forecasting clinical trial results, searching for clinical trial patients, analyzing medical images, analyzing data, developing pharmaceutical products and chemical compounds; downloadable or recorded computer application software for prioritizing targets, assessing tractability and drugability, characterizing patient subgroups, generating reports, validating biomarkers across modalities, and connecting biology to clinical outcomes; downloadable or recorded computer software for database management; software as a medical device (SAMD), downloadable, for diagnosing medical conditions, prescribing medical treatment and prescriptions, and searching for clinical trial patients; downloadable or recorded computer software development tools; computer software platforms, recorded or downloadable, for diagnosing medical conditions, prescribing medical treatment and prescriptions, researching the clinical trial landscape and data, designing clinical trials and forecasting clinical trial results, searching for clinical trial patients, analyzing medical images, analyzing data, developing pharmaceutical products and chemical compounds; computer software platforms, recorded or downloadable, for prioritizing targets, assessing tractability and drugability, characterizing patient subgroups, generating reports, validating biomarkers across modalities, and connecting biology to clinical outcomes; computer programs, recorded, for diagnosing medical conditions, prescribing medical treatment and prescriptions, researching the clinical trial landscape and data, designing clinical trials and forecasting clinical trial results, searching for clinical trial patients, analyzing medical images, analyzing data, developing pharmaceutical products and chemical compounds; computer programs, recorded, for prioritizing targets, assessing tractability and drugability, characterizing patient subgroups, generating reports, validating biomarkers across modalities, and connecting biology to clinical outcomes; electronic publications, downloadable, in the nature of books, magazines, brochures, newsletters, scientific reports, scientific journals, conference proceedings and journals in the fields of medical and biomedical research and development, medical diagnosis and treatment, clinical trials, and drug discovery and development; interfaces for computers; cloud network servers | ACTIVE | — |
| 038 | Telecommunication services, namely, transfer of data by telecommunications; computer intercommunication by computer terminals; communications by computer terminals; computer aided electronic transmission of messages, information and images; transmission of data and information by computer and electronic communication means; communications between data banks by computer terminals; electronic data interchange services; providing multiple-user access to a global computer information network; providing multiple use access to global computer information networks for the transfer and dissemination of a wide range of information; transmission of electronic mail; rental of access time to a computer database on a global computer network; provision of telecommunications access to online databases and the Internet | ACTIVE | — |
| 042 | Software as a service (SAAS) services featuring software for diagnosing medical conditions, prescribing medical treatment and prescriptions, researching the clinical trial landscape and data, designing clinical trials and forecasting clinical trial results, searching for clinical trial patients, analyzing medical images, analyzing data, developing pharmaceutical products and chemical compounds; Software as a service (SAAS) services featuring software for prioritizing targets, assessing tractability and drugability, characterizing patient subgroups, generating reports, validating biomarkers across modalities, and connecting biology to clinical outcomes; scientific and technological services; medical research; scientific research in the medical and biomedical fields | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 15, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 15, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 15, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 27, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 2, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 19, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 19, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 16, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 13, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 2, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 27, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |